Prof. Dhimiter Bello's group at UMass Lowell explored for the first time the utility of nanopore based Tunable Resistive Pulse Sensing (TRPS) technology and optimized its use for characterization of engineered nanomaterial dispersions in cell culture medium containing serum, conditions applicable to in vitro nanotoxicology studies.
Researchers at the National Center for Biodefense and Infectious Diseases, George Mason University recently received the qNano which they used in a new paper, Chung et al. 2014 "Chitinases Are Negative Regulators of Francisella novicida Biofilms" (Open Access).
Prof. Rinti Banerjee and members of her group in the Nanomedicine laboratory at the Department of Biosciences & Bioengineering, Indian Institute of Technology Bombay, are developing smart, trigger responsive biodegradable nanoparticles and nanomaterials for drug delivery and tissue engineering.
Protein aggregation has become a focus for Belgium-based contract laboratory Anabiotec, as it is a key concern in biopharmaceutical production. This is due not only to the risk associated with changes to a products quality or pharmacokinetics, but most importantly because of the hazard of inducing an unwanted immune response, which is more likely to occur with particles in the subvisible and submicron range.
The 3rd International Izon Science Research Symposium will be held in Oxford, UK from 11-12 September 2014. Izon instrument users are invited to submit talks featuring new research using the Tunable Resistive Pulse Sensing (TRPS) platform. We will be organizing the presentations into the following categories: Particle-based Nanomedicine Extracellular Vesicle Analysis Virology, vaccines and gene therapy Colloids, bubbles and other nano- and micro- particle analysis; and TRPS Research and Diagnostic Applications.
Two recent publications demonstrate the use of TRPS as a high sensitivity technique for monitoring the interaction between aptamers and target analytes. The research is important because it demonstrates the potential of the TRPS for high-sensitivity diagnostic assay development.
Izon today announced it has completed a £1 million (NZ$2.0m) funding round in the UK. In conjunction with the investment, Izon’s global headquarters are being transferred from Christchurch to the Oxford Science Park, UK where an Izon subsidiary has been operating since 2010.
The proliferation of nanoparticle-based bioanalytical sensors in recent years has driven the need for improved particle characterization techniques. Precise information on the properties of these particles, including validation of their specific functionality, undoubtedly speeds up assay development.
Izon Science has achieved ISO 13485:2003 quality assurance certification – for the design, development, manufacture and distribution of its nano- and micro-particle characterization systems. “The ISO 13485 certification helps address the QA requirements necessary when tackling markets in bioanalysis, diagnostics, pre-clinical testing and vaccine quality assurance” says Hans van der Voorn, Executive Chairman of Izon Science.
The accuracy of particle characterization is one of the key elements to support any marketing application as all regulatory agencies expect manufacturers to have consistency, between batches, of particle size, concentration, charge and particle size distribution.